DOSAGE INDEX / SINGLE
MGF
Research, reported schedules and supply planning.
Compare MGF osteoblast findings with negative muscle-cell replication research, distinguishing peptide identity, proliferation and functional tissue repair.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–300 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2019 study investigated osteoblasts obtained from newborn rat calvaria. The investigators examined mechanical stretching, splicing-factor activity and MGF-related responses. MGF promoted proliferation and migration in their experiments while inhibiting differentiation through an ERK-associated pathway. This combination of findings is more nuanced than a blanket claim of better bone formation. [3]
- A separate study of human mesenchymal stem cells reported different effects for regions of the MGF prohormone. The mature IGF-1 portion increased proliferation in a small-cell subpopulation, while the E-domain peptide did not show that proliferative effect. The research distinguished migration-related findings from proliferation rather than assigning every response to the same segment. [4]
- No such universal conclusion follows from these studies. The muscle-cell replication paper reported no demonstrated proliferative effect in its tested systems. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 10 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original muscle-cell replication study
- FDA substance record
- Original paper
- Original study
- PLOS ONE (2013)Further reading · Listed in reference bibliography.
- Journal of Molecular Endocrinology (2003)Further reading · Listed in reference bibliography.
- International Orthopaedics (2011)Further reading · Listed in reference bibliography.
- Journal of Physiology (2003)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- Molecular Brain (2017)Further reading · Listed in reference bibliography.
- Experimental Cell Research (2008)Further reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.